Prot #SCRX003-001: A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date9/11/17 → 12/31/20

Funding

  • Novella Clinical, LLC (Prot #SCRX003-001 // Prot #SCRX003-001)
  • AbbVie Stemcentrx LLC (Prot #SCRX003-001 // Prot #SCRX003-001)